Mavrostobart (PT199)

Phase 2Small molecule

PPhanes Therapeutics

Mavrostobart (PT199) is one of 17 small molecule programs targeting PD-1 Inhibitor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PD-1 InhibitorRecruiting

PD-1 InhibitorPhase 2

Recruiting

Competition

Competitive Landscape

16 competitors in PD-1 Inhibitor

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

2 2

Keytruda

Merck & Co.

Phase 2

2 3

Lenvima

Eisai

Phase 2

2 4

Beyfortus

BeiGene

Phase 2

1 5

Eloxatin

Teva

Phase 2

1 6

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 8

Alimta

SShawn Eagle

Phase 2

1 9

Taxotere

AAvyxa

Phase 2

1 10

PD-1 Inhibitor

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1/2Recruiting

PD-1 Inhibitor

NCT05431270

Clinical

Trials by Indication[1]

PD-1 Inhibitor1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Recruiting·PPhanes Therapeutics·Phase 1/2·NCT05431270·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mavrostobart (PT199). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mavrostobart (PT199) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mavrostobart (PT199). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phanes Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPhanes Therapeutics

Mavrostobart (PT199)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

PD-1 Inhibitor1 trial

References

Drug Info

Quick Facts

Related News